Tivozanib (AV-951): Potent VEGFR Inhibitor for Advanced Cancer Research

Principle Overview: The Science Behind Tivozanib (AV-951) in Oncology

Tivozanib (AV-951) is a second-generation, quinoline-urea derivative classified as a highly potent and selective VEGFR tyrosine kinase inhibitor. It targets all three vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3) with picomolar potency, notably displaying an IC₅₀ of 160 pM against VEGFR-2. This exceptional selectivity translates into robust anti-angiogenic effects, minimal off-target activity—including low inhibition of c-KIT—and superior safety in comparison to legacy kinase inhibitors such as sunitinib, sorafenib, and pazopanib.

As a pan-VEGFR inhibitor for cancer therapy, Tivozanib disrupts the VEGFR signaling pathway critical to tumor vascularization and growth. It also inhibits phosphorylation of PDGFRβ and c-KIT at nanomolar concentrations, further broadening its impact in tyrosine kinase inhibitor oncology research. Tivozanib has demonstrated significant antitumor activity in renal cell carcinoma (RCC) xenograft models and supports combination strategies, especially with EGFR-directed agents in multiple solid tumor systems.

For researchers, sourcing high-quality reagents is paramount. APExBIO supplies Tivozanib (AV-951) (SKU: A2251), ensuring consistent performance and lot-to-lot reliability in both basic and translational workflows.

Step-by-Step Workflow: Integrating Tivozanib into Experimental Protocols

Preparation and Storage

• Solubility: Tivozanib is soluble at ≥22.75 mg/mL in DMSO and ≥2.68 mg/mL in ethanol (with gentle warming), but is insoluble in water. Prepare concentrated stocks in DMSO for cell-based studies.
• Storage: Store the solid compound at -20°C. Prepared solutions should be used promptly; avoid long-term storage to ensure integrity.

Cell-Based Assay Protocol Example

1. Cell Seeding: Plate 3,000–5,000 cells per well in a 96-well format, allowing 24 hours for attachment.
2. Compound Treatment: Prepare a working dilution of Tivozanib in complete medium (final DMSO concentration ≤0.1%). For most in vitro assays, 10 μM for 48 hours is standard, but titrate as needed for cell line sensitivity.
3. Readouts: Assess relative viability (e.g., CellTiter-Glo, MTT) and fractional viability (e.g., Annexin V/PI, Caspase-3/7 activity) to distinguish between growth arrest and cell death. As highlighted in Schwartz, 2022, both metrics provide complementary insights into drug response dynamics.
4. Combination Studies: For synergy experiments, co-administer Tivozanib with EGFR inhibitors at varying ratios. Quantify additive, synergistic, or antagonistic effects using Chou-Talalay or Bliss independence models.

Protocol Enhancements

• Time-course profiling: Capture early (24h) and late (72h) responses to map the temporal dynamics of VEGFR signaling pathway inhibition.
• Multiplexed readouts: Incorporate phospho-VEGFR ELISA, Western blotting for p-VEGFR2, or single-cell imaging to dissect pathway-specific versus off-target effects.

Advanced Applications and Comparative Advantages

Renal Cell Carcinoma and Beyond

Tivozanib’s robust antitumor effect is best exemplified in renal cell carcinoma treatment, where it achieves a median progression-free survival (PFS) of 12.7 months in phase III trials—a benchmark among VEGFR inhibitors. Its low off-target toxicity profile enables higher dosing and longer exposure, facilitating extended studies in both in vitro and in vivo models of RCC and other solid tumors.

Combination Therapy with EGFR Inhibitors

Tivozanib’s synergy with EGFR-targeted drugs, particularly in ovarian and colorectal carcinoma models, enhances cell growth inhibition and induces apoptosis more effectively than monotherapy. These findings are supported by published studies, which detail the mechanistic underpinnings and workflow strategies for exploiting this combination in high-throughput screens.

Comparative Performance and Selectivity

Compared to sunitinib, sorafenib, and pazopanib, Tivozanib’s picomolar VEGFR-2 potency and minimal c-KIT/PDGFRβ off-target engagement result in cleaner downstream readouts and reproducible anti-angiogenic effects. As noted in this comparative review, Tivozanib streamlines anti-angiogenic therapy workflows, reduces confounding variables in combination studies, and provides a gold-standard reference for dissecting VEGFR-dependent signaling.

Protocol Extensions and Workflow Complementarity

Protocols outlined in this scenario-driven guide complement Tivozanib-centric studies by addressing reproducibility in cell-based anti-angiogenic assays and offering troubleshooting for data variability. These resources, when combined with APExBIO’s validated supply of Tivozanib, empower labs to benchmark VEGFR inhibition and optimize anti-angiogenic strategies across diverse model systems.

Troubleshooting and Optimization Tips

• Solubility Issues: If Tivozanib precipitates, re-warm the stock solution gently and ensure complete dissolution in DMSO before dilution. Avoid direct addition to aqueous media without prior DMSO solubilization.
• Assay Interference: High DMSO concentrations (>0.5%) can confound viability and enzymatic assays. Keep DMSO at 0.1% final concentration wherever possible.
• Batch Consistency: Use authenticated lots from APExBIO to minimize batch-to-batch variability, especially for long-term studies or comparative screens.
• Data Interpretation: As highlighted in Schwartz's dissertation, distinguish between growth arrest and cell death using both relative and fractional viability metrics. This dual approach ensures accurate assessment of anti-angiogenic therapy effects and prevents overestimation of cytotoxicity.
• Combination Studies: When exploring combination therapy with EGFR inhibitors, use checkerboard titrations and appropriate synergy quantification algorithms to account for non-linear interactions.
• Pathway Specificity: Use phospho-specific antibodies or RT-qPCR for downstream VEGFR targets to confirm on-target activity, especially when cross-referencing with other pan-VEGFR inhibitors.

Future Outlook: Expanding the Role of Tivozanib in Cancer Research

Tivozanib’s unique combination of potency, selectivity, and safety profile positions it as a foundational tool for next-generation anti-angiogenic therapy research. Ongoing efforts to integrate high-content imaging, 3D spheroid models, and patient-derived organoids will further expand its utility in translational oncology. As discussed in emerging strategy analyses, Tivozanib is also being explored in immuno-oncology settings for its potential to modulate tumor microenvironment and enhance immune checkpoint blockade efficacy.

For researchers seeking a VEGFR inhibitor that combines data-backed efficacy with workflow reliability, Tivozanib (AV-951) from APExBIO stands out as a benchmark reagent. Its versatility in monotherapy and combination regimens, coupled with robust performance metrics, makes it an indispensable part of the modern oncology research toolkit.